BioLive Wire · AI-collected
Trump Selects Heidi Overton to Lead FDA, Bloomberg Reports
- President Trump selected Heidi Overton to lead the FDA, according to a Bloomberg report cited by Investing.com.
Published Aug 19Source: Investing.com ↗
NLP · 3-line summary
AI Articles & Report Summaries
Expert articles and reports as a 3-line summary + takeaway
BioLive Wire · AI-collected
BioMarin Stock Surges on $275 Million Alesta Acquisition Deal
- BioMarin Pharmaceutical shares surged after the company announced a $275 million acquisition deal for Alesta, according to an Investing.com report.
Published Aug 18Source: Investing.com ↗
BioLive Wire · AI-collected
Basilea Raises 2026 Profit Outlook on Cresemba Sales Growth
- Swiss pharmaceutical company Basilea raised its 2026 profit outlook, citing sales growth of its antifungal drug Cresemba, according to an Investing.com report.
Published Aug 18Source: Investing.com ↗
BioLive Wire · AI-collected
Cochlear FY Profit Drops 22% but Exceeds Forecasts
- Medical device maker Cochlear reported a 22% drop in full-year profit, though the results exceeded market forecasts, according to an Investing.com report.
Published Aug 18Source: Investing.com ↗
BioLive Wire · AI-collected
Argenx Shares Jump After Positive Phase 3 Results in Autoimmune Myositis Trial
- Argenx shares jumped after the company reported positive Phase 3 results in an autoimmune myositis clinical trial, according to an Investing.com report.
Published Aug 17Source: Investing.com ↗
BioLive Wire · AI-collected
AstraZeneca Scraps Late-Stage Lung Cancer Trial After Data Setback
- AstraZeneca scrapped a late-stage lung cancer clinical trial after a data setback, according to an Investing.com report.
Published Aug 17Source: Investing.com ↗
BioLive Wire · AI-collected
Sandoz to Pay Up to $77 Million for Three Biosimilar Drug Rights From Shanghai Henlius Biotech
- Sandoz agreed to pay up to $77 million for the rights to three biosimilar drugs from Shanghai Henlius Biotech, according to an Investing.com report.
Published Aug 17Source: Investing.com ↗
BioLive Wire · AI-collected
Hutchmed Shares Rise 5% After Positive Phase III Lung Cancer Trial Results
- Hutchmed shares rose 5% after the company reported positive results from a Phase III lung cancer clinical trial, according to an Investing.com report.
Published Aug 17Source: Investing.com ↗
BioLive Wire · AI-collected
AbbVie Raises 2026 Neuroscience Revenue Guidance to $12.7 Billion
- AbbVie now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half, up from $10.8 billion generated last year, according to a Yahoo Finance report.
- Second-quarter neuroscience revenue climbed 20.3% year over year to $3.23 billion, with migraine drugs Ubrelvy and Qulipta rising a combined 22.6%; Q2 immunology revenue reached $8.79 billion, driven by Skyrizi and Rinvoq.
- AbbVie is also developing bretisilocin, a psychedelics-based candidate for major depressive disorder acquired from Gilgamesh Pharmaceuticals, which remains in clinical trials.
Published Aug 16Source: Yahoo Finance ↗
BioLive Wire · AI-collected
Barclays Downgrades Polypeptide After Strong H1 Rally, Samsung Offer
- Barclays downgraded Polypeptide following a strong first-half rally in its shares and a Samsung acquisition offer, according to an Investing.com report.
Published Aug 14Source: Investing.com ↗
BioLive Wire · AI-collected
Valneva Shares Soar to Highest Since May as EMA Validates Key Lyme Vaccine Filing
- Valneva shares soared to their highest level since May after the European Medicines Agency validated a key filing for its Lyme disease vaccine, according to an Investing.com report.
Published Aug 14Source: Investing.com ↗
BioLive Wire · AI-collected
BridgeBio Shares Fall as KKR Launches Secondary Offering
- BridgeBio shares fell after KKR launched a secondary offering of the company's stock, according to an Investing.com report.
Published Aug 13Source: Investing.com ↗
BioLive Wire · AI-collected
Zoetis Gets US FDA Emergency Use Nod for Screwworm Treatment in Dogs
- Zoetis received US FDA emergency use authorization for a treatment for screwworm in dogs, according to an Investing.com report.
Published Aug 13Source: Investing.com ↗
BioLive Wire · AI-collected
Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is Revived
- A lawsuit against Bristol Myers Squibb over a delayed cancer drug was revived, according to an Investing.com report.
Published Aug 13Source: Investing.com ↗
BioLive Wire · AI-collected
As Hims Prepares for Peptides Launch, Wall Street Cautious on Prospects This Year
- As Hims & Hers prepares to launch peptide products, Wall Street remains cautious about its prospects this year, according to an Investing.com report.
Published Aug 12Source: Investing.com ↗
BioLive Wire · AI-collected
Cencora Says Walgreens Volumes Shift, Reaffirms Guidance as Shares Sink
- Cencora said Walgreens-related volumes are shifting and reaffirmed its financial guidance, though shares sank on the news, according to an Investing.com report.
Published Aug 12Source: Investing.com ↗
BioLive Wire · AI-collected
Eli Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide
- Eli Lilly filed lawsuits against six companies over alleged illegal sales of its experimental obesity drug retatrutide, which has not yet received regulatory approval, according to an Investing.com report.
Published Aug 12Source: Investing.com ↗
BioLive Wire · AI-collected
Glenmark's US Unit Settles Humana Antitrust Case for $15.3 Million
- Glenmark's US unit settled an antitrust case with Humana for $15.3 million, according to an Investing.com report.
Published Aug 12Source: Investing.com ↗
BioLive Wire · AI-collected
Vogenx Prices IPO at $13 Per Share, Raising $81.3 Million
- Vogenx priced its IPO at $13 per share, raising $81.3 million, according to an Investing.com report.
Published Aug 11Source: Investing.com ↗
BioLive Wire · AI-collected
Factbox: Global Drugmakers Invest Billions to Boost US Presence
- Global pharmaceutical companies are investing billions of dollars to boost their US presence, according to an Investing.com factbox report.
Published Aug 11Source: Investing.com ↗
BioLive Wire · AI-collected
AdaptHealth to Sell $600 Million Diabetes Business to Cardinal Health
- AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to focus on sleep, respiratory and home medical equipment.
- The company reported 16% second-quarter revenue growth, though its new West Coast capitated contract faced higher-than-expected service costs from utilization and hospital-ordering issues.
Published Aug 11Source: Yahoo Finance ↗
BioLive Wire · AI-collected
Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth
- Hims & Hers raised its annual revenue forecast, citing strong subscriber growth, according to an Investing.com report.
Published Aug 10Source: Investing.com ↗
BioLive Wire · AI-collected
Eli Lilly's Weight-Loss Pill Secures First European Nod in Britain
- Eli Lilly's weight-loss pill secured its first European regulatory approval in Britain, according to an Investing.com report.
Published Aug 10Source: Investing.com ↗
BioLive Wire · AI-collected
Latigo Biotherapeutics Shares Jump 17% After Upsized IPO
- Latigo Biotherapeutics shares jumped 17% after the company's upsized IPO, according to a report.
Published Aug 7Source: Investing.com ↗